James E Flynn
CIK 1352546 · last filed 2024-06-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$307.50M
Companies
34
Total Filings
58
Lifetime Open-Market Net
$142.97M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NUVL | Director | 2,499 | $123.96 | $309.8K | $0 | 2 | 2024-06-14 |
| CareMax, Inc. (CMAXW) Delisted | Director | 15,811,090 | $0.01 | $151.8K | $0 | 1 | 2023-11-21 |
| Oncorus, Inc. (ONCR) Delisted | Director | 1,218,135 | $0.12 | $146.8K | $164.89M | 3 | 2022-12-30 |
| Acutus Medical, Inc. (AFIB) Delisted | Director | — | $0.09 | — | $0 | 1 | 2022-07-05 |
| DA32 Life Science Tech Acquisition Corp. (DALS) Delisted | Director | — | $10.32 | — | $0 | 1 | 2021-08-09 |
| MIRM | 10%+ Owner | 99,325 | $100.65 | $10.00M | -$8.69M | 1 | 2021-07-07 |
| LRMR | Director | 1,943,423 | $4.16 | $8.08M | $48.00M | 1 | 2021-07-02 |
| EWTX | 10%+ Owner | 1,572,960 | $43.52 | $68.46M | $40.00M | 1 | 2021-03-30 |
| LUMOS PHARMA, INC. (LUMO) Delisted | 10%+ Owner | 907,252 | $4.34 | $3.94M | -$13.70M | 1 | 2021-01-08 |
| CalciMedica, Inc. (GRAY) Delisted | 10%+ Owner | 1,853,967 | $5.50 | $10.20M | $200.00M | 1 | 2020-10-01 |
| RVMD | 10%+ Owner | 798,795 | $205.15 | $163.87M | $61.20M | 1 | 2020-02-18 |
| Q32 Bio Inc. (FIXX) Delisted | Director | 0 | $16.82 | $0 | -$64.13M | 2 | 2020-01-31 |
| AdaptHealth Corp. (AHCOW) Delisted | Director | 20,000 | — | — | $0 | 1 | 2019-11-13 |
| ACRS | 10%+ Owner | 1,166,959 | $5.91 | $6.90M | -$18.83M | 1 | 2019-05-13 |
| XERS | 10%+ Owner | 878,518 | $7.93 | $6.97M | -$638.7K | 1 | 2019-01-30 |
| PRTO | Director | 3,742 | $28.14 | $105.3K | $0 | 2 | 2017-12-04 |
| Societal CDMO, Inc. (REPH) Delisted | 10%+ Owner | 407,450 | $2.09 | $851.6K | -$4.24M | 1 | 2017-06-14 |
| EHTH | 10%+ Owner | 1,062,874 | $1.37 | $1.46M | -$7.70M | 2 | 2016-06-02 |
| Larimar Therapeutics, Inc. (ZFGN) Delisted | 10%+ Owner | 46,777 | — | — | $12.08M | 2 | 2016-02-17 |
| AveXis, Inc. (AVXS) Delisted | Director | — | — | — | $0 | 1 | 2016-02-12 |
| ALIMERA SCIENCES INC (ALIM) Delisted | 10%+ Owner | 308,286 | $5.54 | $1.71M | $7.26M | 2 | 2015-12-03 |
| ANTARES PHARMA, INC. (ATRS) Delisted | 10%+ Owner | 3,388,846 | $5.59 | $18.94M | -$16.10M | 3 | 2015-07-17 |
| CAS MEDICAL SYSTEMS INC (CASM) Delisted | 10%+ Owner | 3,200,000 | — | — | $0 | 1 | 2015-01-05 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | 10%+ Owner | 825,603 | $38.22 | $31.55M | $91.43M | 2 | 2014-11-10 |
| ISTA PHARMACEUTICALS INC (ISTA) Delisted | 10%+ Owner | 766,135 | — | — | -$162.52M | 2 | 2011-05-06 |
| MEDICINES CO /DE (MDCO) Delisted | 10%+ Owner | 2,536,035 | — | — | -$22.91M | 1 | 2011-04-01 |
| DUSA | 10%+ Owner | 719,295 | $57.50 | $41.36M | -$21.01M | 1 | 2011-03-17 |
| NeuroMetrix, Inc. (NURO) Delisted | 10%+ Owner | 9 | $4.58 | $41 | $24.64M | 2 | 2010-12-14 |
| HI TECH PHARMACAL CO INC (HITK) Delisted | 10%+ Owner | 210,662 | — | — | -$28.93M | 1 | 2010-12-13 |
| PAR PHARMACEUTICAL COMPANIES, INC. (PRX) Delisted | 10%+ Owner | 1,370,787 | — | — | -$131.60M | 2 | 2009-08-19 |
| EMAGEON INC (EMAG) Delisted | 10%+ Owner | 1,173,658 | $20.38 | $23.91M | -$5.37M | 1 | 2009-03-02 |
| Bio Green Med Solution, Inc. (CYCCP) Delisted | 10%+ Owner | 663,816 | $5.05 | $3.35M | -$730.4K | 1 | 2008-11-14 |
| NITROMED INC (NTMD) Delisted | 10%+ Owner | 1,908,740 | — | — | $1.62M | 4 | 2008-07-25 |
| VIA Pharmaceuticals, Inc. (VIAP) Delisted | 10%+ Owner | 748,013 | — | — | -$1.06M | 3 | 2007-11-07 |
Recent Filings · Page 3 of 6
58 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-08-04 | PRTO | Grant (A) | — | $0 | EDGAR |
| 2017-06-14 | Societal CDMO, Inc. (REPH) Delisted | Sell (S) | −662,682 | -$4.24M | EDGAR |
| 2016-06-02 | EHTH | Sell (S) | −597,048 | -$8.27M | EDGAR |
| 2016-02-17 | Larimar Therapeutics, Inc. (ZFGN) Delisted | Buy (P) | +387,270 | $2.42M | EDGAR |
| 2016-02-12 | AveXis, Inc. (AVXS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-02-11 | Larimar Therapeutics, Inc. (ZFGN) Delisted | Buy (P) | +1,604,958 | $9.66M | EDGAR |
| 2015-12-03 | ALIMERA SCIENCES INC (ALIM) Delisted | Buy (P) | +1,946,016 | $5.84M | EDGAR |
| 2015-10-29 | ALIMERA SCIENCES INC (ALIM) Delisted | Buy (P) | +474,736 | $1.42M | EDGAR |
| 2015-07-17 | ANTARES PHARMA, INC. (ATRS) Delisted | — | — | $0 | EDGAR |
| 2015-07-01 | ANTARES PHARMA, INC. (ATRS) Delisted | Sell (S) | −4,279,332 | -$8.95M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.